Clinical Evaluation of the Use of Desensitizing Agents in the Management of Dentinal Hypersensitivity

Featured Application Dentin hypersensitivity (DH) is a very common global condition which available treatment options are multiple. No gold standard product has been identified, but n-HAP-based therapy recently showed greater DH relief. Dentinal hypersensitivity represents one of the most widespread dental problems and symptoms in the general population. It mainly affects the age group between 18 and 65 years old, presents an incidence of 35%, and may negatively affect the oral health-related quality of life of these patients. This longitudinal study aims to measure dentinal hypersensitivity in adult patients after the use of domiciliary desensitizing devices. In this study, 52 patients were included (32 females and 20 males, mean age: 53 +/- 9.4) At T0 (baseline), patients were instructed to use a desensitizing toothpaste and, at T1, 27 patients reported using sodium monofluorophosphate (1450 ppm) and arginine 8% product (product A), while 25 patients reported using a toothpaste containing n-HAp (nano-hydroxyapatite) in effective dose 2.25% and 0.15% fluoride (1500 ppm) (product B). The study was carried out through three follow up appointments, 14 days apart from one another (T1 and T2). Results showed that the air sensitivity test did not exhibit a significant difference between the time points (p > 0.05), while a significant improvement of DH was recorded for tactile, osmotic, cold thermic, acid, and omni-comprehensive tests in both groups. Both desensitizing agents were effective in reducing DH for different stimuli.